George Antonopoulos, MD
Cardiovascular Disease · Middlebury, CTNPI 1457419814
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,960 of the $12,807 with a category attached, or 70.0%. Novartis accounts for 74.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $10,160 and has fallen 97.8% since, to $219 in 2025.
Across 137 payments — averaging $93.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$10K
- Bard Peripheral Vascular, Inc.$1K
- Abbott$895
- E.r. Squibb & Sons, L.L.C.$451
- Johnson & Johnson$148
- Pfizer$134
- plus $475 from 13 others
What the payments were for
- Speaking & faculty fees$8,96070%
- Travel & lodging$7726%
- Food & beverage$3,04824%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 21 | $9,573 |
| Bard Peripheral Vascular, Inc. | 9 | $1,132 |
| Abbott | 13 | $895 |
| E.r. Squibb & Sons, L.L.C. | 50 | $451 |
| Johnson & Johnson | 8 | $148 |
| Pfizer | 6 | $134 |
| Amgen | 4 | $87 |
| Boehringer Ingelheim | 4 | $73 |
| Bardy Diagnostics, Inc. | 9 | $66 |
| Boston Scientific | 2 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Novo Nordisk | 1 | $27 |
| Heartflow, Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$9,335
- Venclose Maven Catheter$841
- Confirm Rx$247
- RotarexS 6 F x 135 cm$132
- AVEIR$123
- Assurity Pacemaker$112
How this compares
$12,807 in reported general payments places this provider in the 85th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 196 | $143,494 |
| XareltoRivaroxaban | 106 | $68,998 |
| EntrestoSacubitril/Valsartan | 47 | $56,478 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 43 | $9,478 |
| Ranolazine ErRanolazine | 40 | $2,869 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 297 | $2,533 |
| Metoprolol Succinate | 242 | $2,138 |
| Atorvastatin Calcium | 101 | $1,132 |
| Nitroglycerin | 115 | $926 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 37 | $858 |
| Rosuvastatin Calcium | 113 | $844 |
| Nebivolol Hcl | 17 | $683 |
| Carvedilol | 78 | $502 |
| Amlodipine Besylate | 122 | $448 |
| Losartan Potassium | 61 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $134 | $143,494196 claims |
| Johnson & JohnsonXarelto | $148 | $68,998106 claims |
| NovartisEntresto | $9,573 | $56,47847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Middlebury
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
- Antonio FernandezHartford$113K
- Paul ThompsonHartford$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.